{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:02:47Z","timestamp":1789012967412,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.bbmt.2017.08.031","type":"journal-article","created":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T12:45:12Z","timestamp":1504269912000},"page":"127-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease"],"prefix":"10.1016","volume":"24","author":[{"given":"Felipe","family":"Batalini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Econimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Quillen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Mark","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayna","family":"Sarosiek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Brauneis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Havasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Dember","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6307-2445","authenticated-orcid":false,"given":"Vaishali","family":"Sanchorawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2017.08.031_bib0010","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev.med.57.121304.131243","article-title":"Amyloidosis","volume":"57","author":"Pepys","year":"2006","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0015","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/13506129.2016.1257986","article-title":"Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines","volume":"23","author":"Sipe","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0020","doi-asserted-by":"crossref","first-page":"E458","DOI":"10.1002\/ajh.24464","article-title":"Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation","volume":"91","author":"Havasi","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0025","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1001\/archinte.1992.00400230061010","article-title":"Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients","volume":"152","author":"Gertz","year":"1992","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0030","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0035","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1182\/blood-2015-08-662726","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience","volume":"126","author":"Sanchorawala","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0040","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/sj.bmt.1702178","article-title":"Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report","volume":"25","author":"Gertz","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0045","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1046\/j.1523-1755.2003.00813.x","article-title":"High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease","volume":"63","author":"Casserly","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0050","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/ndt\/gfv328","article-title":"The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation","volume":"31","author":"Leung","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0055","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3324\/haematol.13548","article-title":"Treatment of light chain deposition disease with bortezomib and dexamethasone","volume":"94","author":"Kastritis","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0060","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/sj.bmt.1705447","article-title":"Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation","volume":"38","author":"Weichman","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0065","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/bmt.2010.82","article-title":"Long-term outcome of patients with monoclonal Ig deposition disease treated with high-dose melphalan and stem cell transplantation","volume":"46","author":"Girnius","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0070","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1046\/j.1365-2141.2001.03033.x","article-title":"Results of autologous stem cell transplant in multiple myeloma patients with renal failure","volume":"114","author":"Badros","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0075","doi-asserted-by":"crossref","first-page":"823-828","DOI":"10.1038\/sj.bmt.1704440","article-title":"Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant","volume":"33","author":"Lee","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0080","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/bmt.2013.109","article-title":"Long-term outcome of patients with multiple [corrected] myeloma-related advanced renal failure following auto-SCT","volume":"48","author":"Glavey","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0085","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/bmt.2014.226","article-title":"Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure","volume":"50","author":"Bernard","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0090","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","article-title":"High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study","volume":"140","author":"Skinner","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0095","series-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004","first-page":"319","author":"Gertz","year":"2005"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0100","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM199709253371306","article-title":"The systemic amyloidoses","volume":"337","author":"Falk","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0105","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2215\/CJN.02740806","article-title":"Light-chain (AL) amyloidosis: diagnosis and treatment","volume":"1","author":"Sanchorawala","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0110","first-page":"83","author":"Loll","year":"1996","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0115","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/bmt.2010.239","article-title":"A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis","volume":"46","author":"Quillen","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0120","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2015.62.4015","article-title":"Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a Center for International Blood and Marrow Transplant Research study","volume":"33","author":"D'Souza","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0125","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/bmt.2012.170","article-title":"Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis","volume":"48","author":"Gertz","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0130","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/leu.2016.191","article-title":"Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis","volume":"30","author":"Merlini","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166804","article-title":"N-terminal pro-B-type natriuretic peptide as a biomarker for loss of muscle mass in prevalent hemodialysis patients","volume":"11","author":"Ikeda","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0140","doi-asserted-by":"crossref","first-page":"392","DOI":"10.5414\/CNP68392","article-title":"Cardiac biomarkers are influenced by dialysis characteristics","volume":"68","author":"Sommerer","year":"2007","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0145","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1373\/clinchem.2003.030692","article-title":"Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis","volume":"50","author":"Wahl","year":"2004","journal-title":"Clin Chem"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0150","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.2215\/CJN.09001209","article-title":"N-terminal proBNP: marker of cardiac dysfunction, fluid overload, or malnutrition in hemodialysis patients?","volume":"5","author":"Booth","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.bbmt.2017.08.031_bib0155","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ajh.23141","article-title":"Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure","volume":"87","author":"Palladini","year":"2012","journal-title":"Am J Hematol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117306845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117306845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:00:29Z","timestamp":1761058829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879117306845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S1083879117306845"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.08.031","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.08.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}